Literature DB >> 2824753

Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: apparent pA2 analysis.

A J Bertalmio1, J H Woods.   

Abstract

Apparent pA2 values for the opioid antagonist, quadazocine, were used to characterize differential involvement of mu and kappa opioid receptors in the discriminative stimulus effects of opioid agonists. Rhesus monkeys were trained to discriminate s.c. injections of either codeine or ethylketazocine from sham injections. In tests of drug generalization, morphine, levorphanol and alfentanil all produced dose-dependent increases in codeine-appropriate responding, and ethylketazocine produced dose-dependent increases in ethylketazocine-appropriate responding. Quadazocine antagonized the discriminative stimulus effects of each of the agonists. Apparent pA2 values for quadazocine (and slopes of the regression lines fit to the data in "Schild Plot" analysis) were 7.8 (-1.0) with morphine, 7.7 (-1.4) with levorphanol, 7.9 (-0.92) with alfentanil and 5.7 (-0.93) with ethylketazocine. If regression line slopes were constrained to equal -1, 7.8 was the apparent pA2 value with all agonists except ethylketazocine (5.7). This difference in apparent pA2 values for quadazocine confirms that different receptors (mu and kappa, respectively) mediate the discriminative effects of opioid agonists in codeine- and ethylketazocine-trained rhesus monkeys. Also, when the antagonism data were reanalyzed separately for each individual monkey, apparent pA2 values from individual animals were found to be similar to values from other animals in the same group and to values based on grouped data.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824753

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys.

Authors:  C P France; G Winger; M R Seggel; K C Rice; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists.

Authors:  Andrew B Norman; Michael R Tabet; Mantana K Norman; Vladimir L Tsibulsky
Journal:  J Neurosci Methods       Date:  2010-10-23       Impact factor: 2.390

4.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

5.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Local administration of mu or kappa opioid agonists attenuates capsaicin-induced thermal hyperalgesia via peripheral opioid receptors in rats.

Authors:  M C Ko; J E Tuchman; M D Johnson; K Wiesenauer; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

7.  The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Authors:  Megan J Moerke; Andy Z X Zhu; Rachel F Tyndale; Martin A Javors; Lance R McMahon
Journal:  Neuropharmacology       Date:  2016-12-08       Impact factor: 5.250

8.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24

Review 9.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

10.  Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.

Authors:  Caren L Steinmiller; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.